|
1
|
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ and Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol. 6:805–815. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, et al: Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 11(501)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hamid SHM, Whittam D, Mutch K, Linaker S, Solomon T, Das K, Bhojak M and Jacob A: What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 264:2088–2094. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wu Y, Geraldes R, Juryńczyk M and Palace J: Double-negative neuromyelitis optica spectrum disorder. Mult Scler. 29:1353–1362. 2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, Jacob A, Kira JI, Leite MI, Marignier R, et al: Worldwide incidence and prevalence of neuromyelitis optica: A systematic review. Neurology. 96:59–77. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, et al: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 85:177–189. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wingerchuk DM and Lucchinetti CF: Neuromyelitis optica spectrum disorder. N Engl J Med. 387:631–639. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, McKeon A, Costanzi C, Iorio R, Weinshenker BG, et al: Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 81:1197–1204. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Neu N, Duchon J and Zachariah P: TORCH infections. Clin Perinatol. 42:77–103. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lee S, Marrie RA, Fadda G, Freedman MS, Lee L, Muccilli A, Vyas MV, Konig A and Rotstein DL: Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack. Mult Scler. 30:1423–1435. 2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Forouzannia SM, Yarahmadi P, Alirezaei M, Rezaeimanesh N and Naser Moghadasi A: Increased intracranial pressure on a patient with neuromyelitis optica spectrum disorder. Caspian J Intern Med. 12 (Suppl 2):S435–S438. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hayashi Y, Koumura A, Yamada M, Kimura A, Shibata T and Inuzuka T: Acute-onset severe occipital neuralgia associated with high cervical lesion in patients with neuromyelitis optica spectrum disorder. Headache. 57:1145–1151. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tfaily MAH, Titanji B, Schniederjan MJ, Goodman A, Lava NS, Pouch SM, Collins MH and Adelman MW: Neuromyelitis optica presenting as infectious meningoencephalitis: Case report and literature review. Am J Med Sci. 361:534–541. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shi B, Jiang W, He M, Sun H, Sun X, Yang Y, Yao J, Wu L and Huang D: Aseptic meningitis as an atypical manifestation of neuromyelitis optica spectrum disorder flare. Mult Scler Relat Disord. 41(102013)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kim SM, Go MJ, Sung JJ, Park KS and Lee KW: Painful tonic spasm in neuromyelitis optica: Incidence, diagnostic Utility, and clinical characteristics. Arch Neurol. 69:1026–1031. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T and Yamamura T: Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 7(e841)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Içöz S, Tüzün E, Kürtüncü M, Durmuş H, Mutlu M, Eraksoy M and Akman-Demir G: Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci. 120:71–75. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O and Kümpfel T: Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 261:1–16. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, et al: Eculizumab in Aquaporin-4-Positive neuromyelitis optica spectrum disorder. J Neurol. 381:614–625. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Overman RA, Yeh JY and Deal CL: Prevalence of oral glucocorticoid usage in the United States: A general population perspective. Arthritis Care Res (Hoboken). 65:294–298. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ochi H and Fujihara K: Demyelinating diseases in Asia. Curr Opin Neurol. 29:222–228. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, et al: Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 75:1355–1363. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, Amato M P, Asgari N, Banwell B, Bennett J, et al: Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 20:762–772. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wu L, Huang D, Yang Y and Wu W: Combined screening for serum anti-nuclear and anti-aquaporin-4 antibodies improves diagnostic accuracy for distinguishing neuromyelitis optica from multiple sclerosis. Eur Neurol. 72:103–108. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D, Matsushita T, Hayashi F, Yamasaki R, Kuhle J and Kira JI: Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 93:e1299–e1311. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Prüss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, Borowski K, Ahnert-Hilger G, Harms L, Schwab JM, et al: N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 72:902–911. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, et al: Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis. Lancet Neurol. 17:760–772. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wang HS, Kuo MF, Huang SC and Chou ML: Choreoathetosis as an initial sign of relapsing of herpes simplex encephalitis. Pediatr Neurol. 11:341–345. 1994.PubMed/NCBI View Article : Google Scholar
|
